Evidence and speculations: vaccines and therapeutic options for COVID-19 pandemic

References

• Bonilla-Aldana DK, Quintero-Rada K, Montoya-Posada JP, Ramírez-Ocampo S, Paniz-Mondolfi A, Rabaan AA, Sah R, Rodríguez-Morales AJ. SARS-CoV, MERS-CoV and now the 2019-novel CoV: have we investigated enough about coronaviruses?–A bibliometric analysis. Travel Med Infect Dis. 2020;33:101566. doi:10.1016/j.tmaid.2020.101566.
   PubMed Web of Science ®Google Scholar
• Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91–98. doi:10.1016/j.jare.2020.03.005.
   PubMed Web of Science ®Google Scholar
• Gao H, Yao H, Yang S, Li L. From SARS to MERS: evidence and speculation. Front Med. 2016;10(4):377–82. doi:10.1007/s11684-016-0466-7.
   PubMed Web of Science ®Google Scholar
• Báez-Santos YM, John SES, Mesecar AD. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res. 2015;115:21–38. doi:10.1016/j.antiviral.2014.12.015.
   PubMed Web of Science ®Google Scholar
• Khan M, Shereen MA, Khokhar M, Kamil A, Rahman H A novel effective therapeutic approach for treatment of Leishmania tropica through Miltefosine Loaded Chitosan Nanoparticles. 2020.
   Google Scholar
• Rodriguez-Morales AJ, Bonilla-Aldana DK, Tiwari R, Sah R, Rabaan AA, Dhama K. COVID-19, an emerging coronavirus infection: current scenario and recent developments-an overview. J Pure Appl Microbiol. 2020;14(1):6150. doi:10.22207/JPAM.14.1.02.
   Web of Science ®Google Scholar
• Khan S, Nabi G, Han G, Siddique R, Lian S, Shi H, Bashir N, Ali A, Shereen MA. Novel coronavirus: how things are in Wuhan. Clinical Microbiol Infect. 2020;26(4):399. doi:10.1016/j.cmi.2020.02.005.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al. A novel coronavirus from patients with pneumonia in China, 2019. New England J Med. 2020;382(8):727–33. doi:10.1056/NEJMoa2001017.
   PubMed Web of Science ®Google Scholar
• Phan T. Novel coronavirus: from discovery to clinical diagnostics. Infec Gen Evol. 2020;79:104211. doi:10.1016/j.meegid.2020.104211.
   PubMed Web of Science ®Google Scholar
• Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Current Biol. 2020;30(7):1346–1351.e2. doi:10.1016/j.cub.2020.03.022.
   PubMed Web of Science ®Google Scholar
• Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94(7):e00127-20.
   Web of Science ®Google Scholar
• Xiong C, Jiang L, Chen Y, Jiang Q. Evolution and variation of 2019-novel coronavirus. Biorxiv. 2020.
   Google Scholar
• Gao QY, Chen YX, Fang JY. 2019 novel coronavirus infection and gastrointestinal tract. J Dig Dis. 2020;30(3):1346–1351.e2. doi:10.1111/1751-2980.12851.
   Google Scholar
• Chan JF-W, Kok K-H, Zhu Z, Chu H, To KK-W, Yuan S, Yuen K-Y. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Micro Infect. 2020;9(1):221–36. doi:10.1080/22221751.2020.1719902.
   PubMed Web of Science ®Google Scholar
• Chen J. Pathogenicity and transmissibility of 2019-nCoV—a quick overview and comparison with other emerging viruses. Microbes Infect. 2020;22(2):69–71. doi:10.1016/j.micinf.2020.01.004.
   PubMed Web of Science ®Google Scholar
• Khailany RA, Safdar M, Ozaslan M. Genomic characterization of a novel SARS-CoV-2. Gene Rep. 2020;19:100682. doi:10.1016/j.genrep.2020.100682.
   PubMed Web of Science ®Google Scholar
• Khan S, Liu J, Xue M. Transmission of SARS-CoV-2, required developments in research and associated public health concerns. Front Med. 2020;7:310.
   Web of Science ®Google Scholar
• Yu P, Zhu J, Zhang Z, Han Y. A familial cluster of infection associated with the 2019 novel coronavirus indicating possible person-to-person transmission during the incubation period. J Infect Dis. 2020;221(11):1757–61. doi:10.1093/infdis/jiaa077.
   PubMed Web of Science ®Google Scholar
• Nishiura H, Linton NM, Akhmetzhanov AR. Serial interval of novel coronavirus (COVID-19) infections. Inter J Infect Dis. 2020;93:284‒286.
   Web of Science ®Google Scholar
• Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020;11(7):995–98. doi:10.1021/acschemneuro.0c00122.
   PubMed Web of Science ®Google Scholar
• Vetter P, Eckerle I, Kaiser L. Covid-19: a puzzle with many missing pieces. BMJ. 2020:m627. doi:10.1136/bmj.m627.
   PubMedGoogle Scholar
• Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–69.
   Google Scholar
• de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ. Host factors in coronavirus replication. Roles Host Gene Non Cod RNA Exp Virus Infec Springer. 2017;419:1–42.
   Google Scholar
• Millet JK, Whittaker GR. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res. 2015;202:120–34. doi:10.1016/j.virusres.2014.11.021.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–63. doi:10.1126/science.abb2507.
   PubMed Web of Science ®Google Scholar
• Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung S-M, Yuan B, Kinoshita R, Nishiura H. Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data. J Clin Med. 2020;9(2):538. doi:10.3390/jcm9020538.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures. J Med Virol. 2020;92(6):568–76. doi:10.1002/jmv.25748.
   PubMed Web of Science ®Google Scholar
• Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, Chen H, Wang D, Liu N, Liu D, et al. Characteristics of COVID-19 infection in Beijing. J Infect. 2020;80(4):401–06. doi:10.1016/j.jinf.2020.02.018.
   PubMed Web of Science ®Google Scholar
• Shanmugaraj B, Malla A, Phoolcharoen W. Emergence of novel coronavirus 2019-nCoV: need for rapid vaccine and biologics development. Pathogens. 2020;9(2):148. doi:10.3390/pathogens9020148.
   PubMed Web of Science ®Google Scholar
• Favre G, Pomar L, Musso D, Baud D. 2019-nCoV epidemic: what about pregnancies? Lancet (London, England). 2020;395(10224):e40. doi:10.1016/S0140-6736(20)30311-1.
   PubMed Web of Science ®Google Scholar
• Chen S, Huang B, Luo DJ, Li X, Yang F, Zhao Y, Nei X, Huang BX. Pregnant women with new coronavirus infection: a clinical characteristics and placental pathological analysis of three cases. Zhon Bing Li Xue Za Zhi Chin J Pathol. 2020;49:E005–E.
   Google Scholar
• Li Y, Zhao R, Zheng S, Chen X, Wang J, Sheng X, Zhou J, Cai H, Fang Q, Yu F, et al. Lack of vertical transmission of severe acute respiratory syndrome coronavirus. Emerg Infect Dis. 2020;2:1335‒36.(China).
   Google Scholar
• Lee SM, Kang WS, Cho A-R, Kim T, Park JK. Psychological impact of the 2015 MERS outbreak on hospital workers and quarantined hemodialysis patients. Compr Psychiatry. 2018;87:123–27. doi:10.1016/j.comppsych.2018.10.003.
   PubMed Web of Science ®Google Scholar
• Chiang JJ, Cole SW, Bower JE, Irwin MR, Taylor SE, Arevalo J, Fuligni AJ. Depressive symptoms and immune transcriptional profiles in late adolescents. Brain Behav Immun. 2019;80:163–69. doi:10.1016/j.bbi.2019.03.004.
   PubMed Web of Science ®Google Scholar
• Liem A, Wang C, Wariyanti Y, Latkin CA, Hall BJ. The neglected health of international migrant workers in the COVID-19 epidemic. Lancet Psych. 2020;7(4):e20. doi:10.1016/S2215-0366(20)30076-6.
   PubMed Web of Science ®Google Scholar
• Zitting K-M, Münch MY, Cain SW, Wang W, Wong A, Ronda JM, Aeschbach D, Czeisler CA, Duffy JF. Young adults are more vulnerable to chronic sleep deficiency and recurrent circadian disruption than older adults. Sci Rep. 2018;8(1):1–14. doi:10.1038/s41598-018-29358-x.
   PubMed Web of Science ®Google Scholar
• Liu S, Yang L, Zhang C, Xiang Y-T, Liu Z, Hu S, Zhang B. Online mental health services in China during the COVID-19 outbreak. Lancet Psych. 2020;7(4):e17–e8. doi:10.1016/S2215-0366(20)30077-8.
   PubMed Web of Science ®Google Scholar
• Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58–60. doi:10.5582/ddt.2020.01012.
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):1–14. doi:10.1038/s41467-019-13940-6.
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71. doi:10.1038/s41422-020-0282-0.
   PubMed Web of Science ®Google Scholar
• Jean -S-S, Lee P-I, Hsueh P-R. Treatment options for COVID-19: the reality and challenges. J Micro Bio Immunol Infec. 2020;53(3):436–43. doi:10.1016/j.jmii.2020.03.034.
   PubMed Web of Science ®Google Scholar
• Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018:9(2).
   Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, et al. Remdesivir for the treatment of Covid-19—preliminary report. New England J Med. 2020. doi:10.1056/NEJMoa2007764.
   Google Scholar
• Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. 2020. doi:10.1016/j.eng.2020.03.007.
   Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. New England J Med. 2020;382(19):1787–99. doi:10.1056/NEJMoa2001282.
   PubMed Web of Science ®Google Scholar
• Baden LR, Rubin EJ. Covid-19—the search for effective therapy. N Engl J Med. 2020; 382:1851‒1852
   Google Scholar
• Luo H, Tang Q-L, Shang Y-X, Liang S-B, Yang M, Robinson N, Liu JP. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med. 2020;17:1–8.
   Web of Science ®Google Scholar
• Klasse PJ, Moore JP. Antibodies to SARS-CoV-2 and their potential for therapeutic passive immunization. Elife. 2020.
   Google Scholar
• Derebail VK, Falk RJ. ANCA-associated vasculitis—refining therapy with plasma exchange and glucocorticoids. N Engl J Med 2020; 382:671‒673
   Google Scholar
• Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang, March F, Li D, Yang M, et al. Posting date. Treatment of 5 critically ill patients with COVID19 with convalescent plasma. JAMA. 2020;323(16):1582. doi:10.1001/jama.2020.4783.
   PubMed Web of Science ®Google Scholar
• Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother. 20202;16(6):1232‒1238.
   Web of Science ®Google Scholar
• Pinto D, Park Y-J, Beltramello M, Walls AC, Tortorici MA, Bianchi S, Jaconi S, Culap K, Zatta F, De Marco A. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;18:1–6.
   Web of Science ®Google Scholar
• Garg AD, Coulie PG, Van den Eynde BJ, Agostinis P. Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape. Trends Immunol. 2020;7:577–93. doi:10.1016/j.it.2017.05.006.
   Google Scholar
• Nace G, Evankovich J, Eid R, Tsung A. Dendritic cells and damage-associated molecular patterns: endogenous danger signals linking innate and adaptive immunity. J Innate Immun. 2012;4(1):6–15. doi:10.1159/000334245.
   PubMed Web of Science ®Google Scholar
• Le TT, Andreadakis Z, Kumar A, Roman RG, Tollefsen S, Saville M, Mayhew S. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305–06. doi:10.1038/d41573-020-00073-5.
   PubMed Web of Science ®Google Scholar
• Sherley JL, Prentice D An ethics assessment of COVID-19 vaccine programs.
   Google Scholar
• ClinicalTrials.gov. Immunity and safety of Covid-19 synthetic minigene vaccine. 2020.
   Google Scholar
• Kruse RL. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Research. 2020;9:72.
   Google Scholar
• Somasundaram R, Choraria A, Antonysamy M. An approach towards development of monoclonal IgY antibodies against SARS CoV-2 spike protein (S) using phage display method: A review. Int Immunopharmacol. 2020;85:106654. doi:10.1016/j.intimp.2020.106654.
   PubMed Web of Science ®Google Scholar
• Palaniyappan A, Das D, Kammila S, Suresh MR, Sunwoo HH. Diagnostics of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid antigen using chicken immunoglobulin Y. Poult Sci. 2012;91:636–42. doi:10.3382/ps.2011-01916.
   PubMed Web of Science ®Google Scholar
• Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, Schäfer A, Reidy JX, Trivette A, Nargi RS, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020:584:443‒9.
   PubMed Web of Science ®Google Scholar
• de Alwis R, Chen S, Gan ES, Ooi EE. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development. EBioMedicine. 2020:102768. doi:10.1016/j.ebiom.2020.102768.
   PubMed Web of Science ®Google Scholar
• He C, Qin M, Sun X. Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight. Acta Pharm Sin B. 2020;10(7):1175–91. doi:10.1016/j.apsb.2020.05.009.
   PubMed Web of Science ®Google Scholar
• Guo Y, Sun S, Wang K, Zhang S, Zhu W, Chen Z. Elicitation of immunity in mice after immunization with the S2 subunit of the severe acute respiratory syndrome coronavirus. DNA Cell Biol. 2005;24:510–15. doi:10.1089/dna.2005.24.510.
   PubMed Web of Science ®Google Scholar
• Li J, Ulitzky L, Silberstein E, Taylor DR, Viscidi R. Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates. Viral Immunol. 2013;26:126–32. doi:10.1089/vim.2012.0076.
   PubMed Web of Science ®Google Scholar
• McKay B Drugmakers rush to develop vaccines against china virus. The Wall Street Journal Available online: https://www wsj com/articles/drugmakers-rush-to-develop-vaccines-against-china-virus-11579813026 (accessed on 23 March 2020).
   Google Scholar
• Yi C, Yi Y, Li J. mRNA vaccines: possible tools to combat SARS-CoV-2. Virol Sin. 2020;35:259‒62.
   Web of Science ®Google Scholar
• Smith J CureVac bids to develop first mRNA coronavirus vaccine. 2020.
   Google Scholar
• Park A. Inside the company that’s hot-wiring vaccine research in the race to combat the coronavirus. Time. 2020;2020.
   Google Scholar
• de Vries APJ, Alwayn IPJ, Hoek RAS, van den Berg AP, Ultee FCW, Vogelaar SM, Haase-Kromwijk BJ, Heemskerk MB, Hemke AC, Nijboer WN. Coronavirus dashboard (COVID-19)-update log. J Am Soc Nephrol. 2020.
   Google Scholar
• Inovio IP Inovio selected by cepi to develop vaccine against new coronavirus inovio.
   Google Scholar
• Technology P. University of Waterloo to develop nasal vaccine for Covid-19. Pharmaceutical Technology; 2020.
   Google Scholar
• Onyeador O Cobra and the KI collaborate to develop COVID-19 vaccine. PRODUCT & INDUSTRY NEWS, 2020.
   Google Scholar
• ClinicalTrials.gov. Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19. 2020.
   Google Scholar
• Cheung E China coronavirus: hong Kong researchers have already developed vaccine but need time to test it, expert reveals. 2020.
   Google Scholar
• News GR. GeoVax and BravoVax (Wuhan, China) to collaborate on development of coronavirus vaccine. 2020.
   Google Scholar
• Biopharmaceuticals C. Clover initiates development of recombinant subunit-trimer vaccine for wuhan coronavirus (2019-nCoV). 2020.
   Google Scholar
• Johnson. Our COVID-19 response efforts. 2020.
   Google Scholar
• Codagenix I. Codagenix and Serum Institute of India Initiate Co-Development of a Scalable, Live-Attenuated Vaccine Against the 2019 Novel Coronavirus, COVID-19. 2020.
   Google Scholar
• Hennessy J. Australia’s been asked to make a coronavirus vaccine at ‘unprecedented speed. Sci Alert. 2020.
   Google Scholar
• Vaxart. Vaxart announces initiation of coronavirus vaccine program. 2020.
   Google Scholar
• Mukherjee S The first coronavirus drug candidate is set for testing in China. 2020.
   Google Scholar
• Radcliffe S Here’s exactly where we are with vaccines and treatments for COVID-19. 2020.
   Google Scholar
• Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, et al. Rapid development of an inactivated vaccine for SARS-CoV-2. bioRxiv. 2020.
   Google Scholar
• Liu A China’s CanSino Bio advances COVID-19 vaccine into phase 2 on preliminary safety data. 2020.
   Google Scholar
• Sanofi. Sanofi’s Response in the Fight against COVID-19. SanofiFacts. 2020.
   Google Scholar
• Stanton D. Merck betting on ‘swish-and-swallow’ and single administration COVID vaccines. Bioprocess Int. 2020.
   Google Scholar
• Technology P. Coronavirus: vir Biotechnology and Novavax announce vaccine plans. 2020.
   Google Scholar
• Mestrovic T PiCoVacc vaccine candidate for COVID-19 effective in animal trials. 2020.
   Google Scholar
• Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. New England J Med. 2020;382:1969–73. doi:10.1056/NEJMp2005630.
   PubMed Web of Science ®Google Scholar
• Rogers J CEPI-funded COVID-19 vaccine candidates progress to clinical trials. 2020.
   Google Scholar
• World Health O. DRAFT landscape of COVID-19 candidate vaccines. World; 2020.
   Google Scholar
• Gouglas D, Le TT, Henderson K, Kaloudis A, Danielsen T, Hammersland NC, Robinson JM, Heaton PM, Røttingen J-A. Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. Lancet Global Health. 2018;6:e1386–e96. doi:10.1016/S2214-109X(18)30346-2.
   PubMed Web of Science ®Google Scholar
• Mullard A. COVID-19 vaccine development pipeline gears up. Lancet. 2020;395:1751–52. doi:10.1016/S0140-6736(20)31252-6.
   PubMed Web of Science ®Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bitaye M, Clutterbuck AE, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020.
   Google Scholar